EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Drug-Induced Pneumonitis Secondary to Ribociclib in a Patient With Metastatic Breast Cancer

Zoha Mustafa, Maisoun Ahmad, Mohammed Alkhatib, Irfan Ul Haq, Mona Allangawi, Merlin Thomas, Mansoor Hameed

Cureus · 13.04.2026

DOI: 10.7759/cureus.106954 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cureus, erschienen am 13.04.2026. Verfasst von Zoha Mustafa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medicine, Royal College of Surgeons in Ireland, Manama, BHR. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

cdk4/6 inhibitorsinterstitial lung diseasemetastatic breast cancerpneumonitisribociclib

Autor:innen und Institutionen

  • Medicine, Royal College of Surgeons in Ireland, Manama, BHR.
  • Pulmonary Medicine, Hamad Medical Corporation, Doha, QAT.
  • Medicine, Qatar University, Doha, QAT.
  • Medicine, Weill Cornell Medicine - Qatar, Doha, QAT.
  • Pulmonary Medicine, Hamad General Hospital, Doha, QAT.

Zitieren

APA

Mustafa, Z., Ahmad, M., Alkhatib, M., Haq, I. U., Allangawi, M., Thomas, M., & Hameed, M. (2026). Drug-Induced Pneumonitis Secondary to Ribociclib in a Patient With Metastatic Breast Cancer. Cureus. https://doi.org/10.7759/cureus.106954

Vancouver

Mustafa Z, Ahmad M, Alkhatib M, Haq IU, Allangawi M, Thomas M, et al. Drug-Induced Pneumonitis Secondary to Ribociclib in a Patient With Metastatic Breast Cancer. Cureus. 2026. doi:10.7759/cureus.106954

BibTeX
@article{Mustafa2026,
  author = {Mustafa, Zoha and Ahmad, Maisoun and Alkhatib, Mohammed and Haq, Irfan Ul and Allangawi, Mona and Thomas, Merlin and Hameed, Mansoor},
  title = {Drug-Induced Pneumonitis Secondary to Ribociclib in a Patient With Metastatic Breast Cancer},
  journal = {Cureus},
  year = {2026},
  doi = {10.7759/cureus.106954}
}
Kostenlos starten →